DelveInsight’s “Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Functional Dyspepsia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Functional Dyspepsia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Functional Dyspepsia Market Insights
Functional Dyspepsia Overview
Functional Dyspepsia (FD) is a term for recurring signs and symptoms of indigestion that have no obvious cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. The etiology of functional dyspepsia is likely heterogeneous and multifactorial; however, the exact cause is not clearly understood.
Some of the key facts of the Functional Dyspepsia Market Report:
- The Functional Dyspepsia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to a research article published in April 2021, acotiamide immediate release 300 mg once daily was found to have similar efficacy and safety as acotiamide immediate release 100 mg three times daily. Throughout the course of a four-week therapy session, patients with FD-PDS showed a significant improvement in QoL.
- Large corporations are creating possible pharmacological candidates to enhance the Functional Dyspepsia therapy situation, including Zeria, Renexxion, and others.
- In a Korean, a study completed the Rome III questionnaire where, 7.7% had dyspepsia; postprandial distress was reported by 5.6% and EPS by 4.2%, while 27% had both PDS and EPS
- According to AC et al., 2020, approximately 80% of individuals with dyspepsia have no structural explanation for their symptoms and have functional dyspepsia. Functional dyspepsia affects up to 16% of otherwise healthy individuals in the general population
- Key Functional Dyspepsia Companies: Zeria Pharmaceutical, Renexxion, RaQualia Pharma, Tsumura and Company, and others
- Key Functional Dyspepsia Therapies: Acofide, Naronapride, Rikkunshito, and others
- The Functional Dyspepsia epidemiology based on gender analyzed that Functional Dyspepsia affects females more than males
Get a Free sample for the Functional Dyspepsia Market Report –
https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights
Key benefits of the Functional Dyspepsia Market report:
- Functional Dyspepsia market report covers a descriptive overview and comprehensive insight of the Functional Dyspepsia Epidemiology and Functional Dyspepsia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Functional Dyspepsia market report provides insights on the current and emerging therapies.
- Functional Dyspepsia market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Functional Dyspepsia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Functional Dyspepsia market.
Download the report to understand which factors are driving Functional Dyspepsia epidemiology trends @ Functional Dyspepsia Epidemiological Insights
Functional Dyspepsia Market
The dynamics of the Functional Dyspepsia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Functional Dyspepsia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Functional Dyspepsia Epidemiology Segmentation:
The Functional Dyspepsia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Functional Dyspepsia
- Prevalent Cases of Functional Dyspepsia by severity
- Gender-specific Prevalence of Functional Dyspepsia
- Diagnosed Cases of Episodic and Chronic Functional Dyspepsia
Functional Dyspepsia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Functional Dyspepsia market or expected to get launched during the study period. The analysis covers Functional Dyspepsia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Functional Dyspepsia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Functional Dyspepsia market share @ Functional Dyspepsia market forecast
Functional Dyspepsia Therapies and Key Companies
- Acofide: Zeria Pharmaceutical
- Naronapride: Renexxion
- Rikkunshito: Tsumura and Company, Tokyo, Japan
Scope of the Functional Dyspepsia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Functional Dyspepsia Companies: Zeria Pharmaceutical, Renexxion, RaQualia Pharma, Tsumura and Company, and others, and others
- Key Functional Dyspepsia Therapies: Acofide, Naronapride, Rikkunshito, and others
- Functional Dyspepsia Therapeutic Assessment: Functional Dyspepsia current marketed and Functional Dyspepsia emerging therapies
- Functional Dyspepsia Market Dynamics: Functional Dyspepsia market drivers and Functional Dyspepsia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Functional Dyspepsia Unmet Needs, KOL’s views, Analyst’s views, Functional Dyspepsia Market Access and Reimbursement
Table of Contents
1. Functional Dyspepsia Market Report Introduction
2. Executive Summary for Functional Dyspepsia
3. SWOT analysis of Functional Dyspepsia
4. Functional Dyspepsia Patient Share (%) Overview at a Glance
5. Functional Dyspepsia Market Overview at a Glance
6. Functional Dyspepsia Disease Background and Overview
7. Functional Dyspepsia Epidemiology and Patient Population
8. Country-Specific Patient Population of Functional Dyspepsia
9. Functional Dyspepsia Current Treatment and Medical Practices
10. Functional Dyspepsia Unmet Needs
11. Functional Dyspepsia Emerging Therapies
12. Functional Dyspepsia Market Outlook
13. Country-Wise Functional Dyspepsia Market Analysis (2019–2032)
14. Functional Dyspepsia Market Access and Reimbursement of Therapies
15. Functional Dyspepsia Market Drivers
16. Functional Dyspepsia Market Barriers
17. Functional Dyspepsia Appendix
18. Functional Dyspepsia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Functional Dyspepsia treatment, visit @ Functional Dyspepsia Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis